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OBJECTIVE — Alstro ¨m syndrome, with type 2 diabetes, and blindness could confer a high
riskoffootulceration.ClinicaltestingforneuropathyinAlstro ¨msyndromeandmatchedyoung-
onset type 2 diabetic subjects was therefore undertaken.
RESEARCH DESIGN AND METHODS — Fifty-eight subjects with Alstro ¨m syndrome
(18 insulin-resistant nondiabetic and 40 diabetic; aged 8–43 years) and 30 young-onset diabetic
subjects (aged 13–35 years) were studied. Neuropathy symptom questionnaires were administered.
Graded monoﬁlament and 128-MHz tuning fork vibration perception were assessed in both feet.
RESULTS — Neuropathicsymptoms,lossofmonoﬁlament,and/orvibrationperceptionwere
reportedby12ofthe30young-onsettype2diabeticsubjects(6hadneuropathiculceration)but
none of the subjects with Alstro ¨m syndrome.
CONCLUSIONS — The strikingpreservationofprotectivefootsensationinAlstro ¨msyndrome
may provide a clue to the causes of differential susceptibility to neuropathy in the wider diabetic
population.
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A
lstro ¨m syndrome is a rare autoso-
mal recessive condition character-
ized by cone-rod dystrophy and
childhood blindness, obesity and insulin
resistance leading to type 2 diabetes in
adolescence, and hyperlipidemia (1,2).
Mutations in the ALMS1 gene have been
described in the majority of cases (3,4).
The accompanying blindness might in-
creasetheriskoffootulcerationifperiph-
eral neuropathy were to develop.
Therefore, a systematic foot examination
of 58 subjects with Alstro ¨m syndrome
and 30 young-onset type 2 diabetic sub-
jects was undertaken.
RESEARCH DESIGN AND
METHODS— Ethics committees of
Torbay Hospital, Bristol Royal Hospital
forChildren,andTheJacksonLaboratory
gave study approval. Subjects with Al-
stro ¨m syndrome were studied at Alstro ¨m
Syndrome U.K. and Alstro ¨m Syndrome
International clinics. Fifty-eight subjects
with Alstro ¨m syndrome and 30 young-
onset (25 years of age at diagnosis) type
2diabeticsubjects;10of12patientsfrom
the adolescent type 2 diabetes register at
Bristol Royal Hospital for Children; and
20 of 22 patients from the diabetes retinal
screeningregisterofSouthDevonHealth-
care, Torbay Hospital were included.
Clinical protocol
A validated questionnaire (available in an
online appendix at http://dx.doi.org/10.
2337/dc08-1584) seeking symptoms of
bilateral neuropathic pain was adminis-
tered to all subjects by three trained in-
vestigators. Research-grade 2-, 4-, 6-, 8-,
10-, and 15-g monoﬁlaments (Bailey
Instruments, Manchester, U.K.) and
128-MHz tuning forks were used to test
for protective sensation in subjects with
eyes closed (5) (see Clinical Protocol
available in the online appendix). Brieﬂy,
monoﬁlaments were bounced to warm
them up and applied ﬁrmly to six sites on
each foot with a variable pause between
tests to exclude false-positive responses.
Calloused sites were avoided. Preserva-
tion of vibration perception was recorded
if the subject sensed vibration at the tip of
the hallux for 3 s and correctly identiﬁed
when damped. Serum lipids and A1C
were taken from patient records in the
U.S. and from clinical laboratories at Tor-
bay Hospital and Bristol Royal Hospital
for Children in the U.K.
Statistics
For statistical testing, parametric ANOVA
was used for BMI and A1C and the
Kruskal-Wallis test was used for mono-
ﬁlaments.Forpulses,128V,andreﬂexes,
Fisher’s exact test was used. Statistical
computations were performed with
Foundation for Statistical Computing
software (R2.6.1; http://www.r-project.
org). The signiﬁcance threshold was set
at P  0.05.
RESULTS— The Alstro ¨m diabetic
subjects (n  40) and young-onset type 2
diabetic patients (n  30) are well
matched (Table A1 of the online appen-
dix) except for duration of diabetes,
which is longer in the Alstro ¨m diabetic
group:fortype2diabetesvs.Alstro ¨msyn-
drome diabetes, respectively, duration of
diabetes 4.6  3.2 vs. 13.8  2.8 years;
A1C 8.6  2.5 vs. 9.1  1.5%, P  0.14;
serum cholesterol 5.3  0.9 vs. 6.1  1.3
mmol/l, P  0.25; and serum triglyceride
3.7  1.9 vs. 0.8  6.0 mmol/l, log-
transformed P  0.15. Table 1 shows the
prevalence of neuropathic symptoms and
loss of protective sensation in each group
of subjects. No Alstro ¨m syndrome sub-
jects manifested typical neuropathic pain
or absence of vibration perception. All
perceived 6-g monoﬁlament stimuli at all
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None had present or past foot ulcers.
In contrast, neuropathic symptoms,
absent vibration perception, or impair-
ment of 6-g or 10-g monoﬁlament percep-
tion was found in 14, 11, 7, and 12 of the
control young-onset type 2 diabetic sub-
jects, respectively. Six had neuropathic
ulcers, and one had a bilateral ulcer.
Statistical analysis showed highly sig-
niﬁcant differences between Alstro ¨m syn-
drome diabetic and young-onset type 2
diabetic patients with respect to presence
of neuropathic symptoms (P  0.0001),
absence of vibration perception (P 
0.004), and mean lightest perceived
monoﬁlament (P  0.00001).
CONCLUSIONS — Impairment of
vibrationsenseand/ormonoﬁlamentper-
ception at 10 g is strongly predictive of
future ulceration in diabetes (6,7). Our
ﬁndings with graded monoﬁlaments and
vibration perception have conﬁrmed the
high prevalence of peripheral sensory
loss, neuropathy, and ulceration in a
small group of young/adolescent-onset
type 2 diabetic individuals.
Alstro ¨m syndrome diabetic subjects
maintained good protective sensation de-
spite comparable hyperglycemia and dys-
lipidemia (online appendix). This ﬁnding
isencouraging,asitconﬁrmsthatAlstro ¨m
syndrome subjects can undertake exer-
cise and domestic activities with low risk
offootulceration.Thefreedomfromclin-
ical signs of neuropathy suggests the pos-
sibility of a protective factor, associated
with the syndrome, that may, when iden-
tiﬁed, increase understanding of the
causesofdiabeticneuropathyandsuggest
novel therapeutic interventions. Studies
of nerve conduction in these patients are
needed to conﬁrm these ﬁndings.
Alstro ¨m syndrome patients could be
protected from clinical diabetic neuropa-
thy because of their short stature (8,9),
though the mean height for Alstro ¨m syn-
drome patients was not signiﬁcantly dif-
ferent from that for control subjects. It
was recently reported that patients with
Alstro ¨m syndrome have subtle impair-
ments in the growth hormone–IGF axis
with a reduction in acid labile subfraction
and IGF binding protein-1, whereas IGF
binding protein-2 was shown to be mark-
edly increased (10). These alterations
could protect against microvascular com-
plicationsasinthesex-linkedformofate-
liotic dwarﬁsm (11,12).
The ﬁnding that the ALMS1 protein
localizes intracellularly to the centrosome
andmaythereforeinﬂuencemicrotubular
function has led to speculation that trans-
portofGLUT1–5receptorstothecellsur-
face may be impaired in Alstro ¨m
syndrome (13). Underexpression of
GLUT1 receptors might protect neurons
from hyperglycemic metabolic insult in
those with diabetes and Alstro ¨m syn-
drome. Further studies evaluating the
roles of ALMS1 protein and microtubular
functioninnormalneuronalfunctionand
neuropathies are strongly indicated.
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